Biomark Diagnostics
Market Cap
€9.0m
Last Updated
2020/02/23 23:57 UTC
Data Sources
Company Financials
Executive Summary
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Worrying balance sheet with weak fundamentals.
Share Price & News
How has Biomark Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 20B's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-1.6%
20B
0.4%
DE Biotechs
-0.9%
DE Market
1 Year Return
416.7%
20B
10.0%
DE Biotechs
12.8%
DE Market
Return vs Industry: 20B exceeded the German Biotechs industry which returned 10% over the past year.
Return vs Market: 20B exceeded the German Market which returned 12.8% over the past year.
Shareholder returns
| 20B | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.6% | 0.4% | -0.9% |
| 30 Day | -20.5% | -3.2% | -0.4% |
| 90 Day | -26.2% | 4.6% | 2.3% |
| 1 Year | 416.7%416.7% | 10.3%10.0% | 16.3%12.8% |
| 3 Year | 113.8%113.8% | 49.4%47.8% | 15.8%5.7% |
| 5 Year | -50.8%-50.8% | 13.9%11.5% | 19.7%3.3% |
Price Volatility Vs. Market
How volatile is Biomark Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
We Think Biomark Diagnostics (FRA:20B) Can Afford To Drive Business Growth11 months ago | Simply Wall St
The Biomark Diagnostics (FRA:20B) Share Price Is Down 69% So Some Shareholders Are Wishing They Sold1 year ago | Simply Wall St
Biomark Diagnostics Inc (FRA:20B): How Does It Impact Your Portfolio?Valuation
Is Biomark Diagnostics undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Biomark Diagnostics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Biomark Diagnostics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Take a look at our analysis of 20B’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Biomark Diagnostics regulatory filings.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
Future Growth
How is Biomark Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
35.7%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biomark Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Take a look at our analysis of 20B’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- Biomark Diagnostics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Biomark Diagnostics performed over the past 5 years?
43.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 20B is currently unprofitable.
Growing Profit Margin: 20B is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 20B is unprofitable, but has reduced losses over the past 5 years at a rate of 43% per year.
Accelerating Growth: Unable to compare 20B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 20B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 20B's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Biomark Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: 20B has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 20B has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 20B is debt free.
Reducing Debt: 20B's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Inventory Level: 20B has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 20B's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 20B has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 20B has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Biomark Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 20B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 20B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 20B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 20B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 20B's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.7yrs
Average management tenure
CEO
Rashid Bux 0
5.7yrs
Tenure
CA$240,000
Compensation
Mr. Rashid Ahmed Bux, B.Sc., MBA, is the Founder of BioMark Technologies Inc., a bio pharm business, which has achieved Phase III status in an unprecedented 3 years and has been it Chief Executive Officer ...
CEO Compensation Analysis
Compensation vs Market: Rashid's total compensation ($USD181.63K) is below average for companies of similar size in the German market ($USD413.13K).
Compensation vs Earnings: Rashid's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5.7yrs | CA$240.00k | 0.41% CA$37.2k | |
| CFO & Project Director | 2.7yrs | no data | no data | |
| Chief Scientific Officer | 0yrs | no data | no data | |
| Chief Financial Officer of US | 0yrs | no data | no data | |
| Principal Scientific Advisor | 0yrs | no data | no data | |
| Chief of Surrey Hospital Thoracic Surgery Team | 1.1yrs | no data | no data |
2.7yrs
Average Tenure
Experienced Management: 20B's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5.7yrs | CA$240.00k | 0.41% CA$37.2k | |
| Member of Media Advisory Board | 0yrs | no data | no data | |
| Independent Director | 5.4yrs | no data | no data | |
| Independent Director | 5.4yrs | no data | no data |
5.4yrs
Average Tenure
Experienced Board: 20B's board of directors are considered experienced (5.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 20B insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.
Top Shareholders
Company Information
Biomark Diagnostics Inc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biomark Diagnostics Inc
- Ticker: 20B
- Exchange: DB
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €8.967m
- Shares outstanding: 72.31m
- Website: https://www.biomarkdiagnostics.com
Location
- Biomark Diagnostics Inc
- 165–10551 Shellbridge Way
- Richmond
- British Columbia
- V6X 2W8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BUX | CNSX (Canadian National Stock Exchange) | Yes | Common Shares | CA | CAD | Nov 2014 |
| 20B | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Nov 2014 |
| BMKD.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Nov 2014 |
Biography
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allow for cancer detection, monitoring, and assessing treatment. The company has a research collaboration with the University of Maryland School of Medicine related to the discovery and validation of biomarkers using a combinatorial technology approach. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/23 23:57 |
| End of Day Share Price | 2020/02/21 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.